STAAR Surgical Company - 10-K Summary (Fiscal Year Ended Dec 29, 2000)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 29, 2000. STAAR Surgical Company is a developer, manufacturer, and global distributor of ophthalmic products, primarily Intraocular Lenses (IOLs) for cataract surgery, Implantable Contact Lenses (ICLs) for refractive correction, and the AquaFlow device for glaucoma. The company operates as a single business segment with significant international exposure, particularly in Europe.
The year was marked by significant management turnover, including the termination of the former CEO and the appointment of David Bailey as President and CEO in December 2000. The company also executed a major strategic realignment to discard unprofitable lines and restructure operations.
Key Financial Metrics
| Metric | 2000 | 1999 |
|---|---|---|
| Total Revenues | $54.4 million | $59.2 million |
| Gross Profit | $28.1 million (51.6% margin) | $36.3 million (61.3% margin) |
| Net Income (Loss) | ($18.9 million) | $2.2 million |
| Diluted EPS | ($1.23) | $0.15 |
| Operating Cash Flow | ($5.4 million) used | $4.9 million provided |
| Working Capital | $24.3 million | $28.2 million |
| Cash and Equivalents | $6.1 million | $3.3 million |
| Debt (Notes Payable) | $7.9 million | $3.2 million |
Note: The 2000 net loss includes a $13.8 million restructuring charge and a $4.7 million write-off of a Japanese joint venture. Excluding these charges, the company reported a net loss of $0.8 million for 2000.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 8.4% to $54.4 million. Drivers included the strength of the U.S. dollar against foreign currencies (specifically the German Mark), decreased sales to the Canon joint venture, and lower average selling prices for ICLs due to a shift to distributor sales.
- Margin Compression: Gross margin fell from 61.3% to 51.6%. This was primarily due to a $5.2 million inventory write-off and higher unit costs for the new Collamer IOL product mix.
- Restructuring Charges: The company recorded a $13.8 million pretax charge in Q2 2000. This included $4.1 million in severance, $4.0 million in patent write-offs, $1.9 million for abandoned activities (Lasik market exit), and $1.0 million for closing a foreign subsidiary.
- Joint Venture Write-off: A $4.7 million charge was recorded to write off the investment in the Canon-STAAR joint venture in Japan due to ongoing arbitration and concerns over recoverability.
- Capital Structure: The company completed a private placement of 1.5 million shares in October 2000, raising net proceeds of $18.7 million. These funds were used to pay off long-term term debt and reduce the line of credit.
Guidance, Outlook, and Risks
Outlook and Product Pipeline:
- ICL (Implantable Contact Lens): Phase III clinical trials for myopia are complete; a Pre-Market Approval (PMA) application is anticipated in early 2002. Hyperopia trials are ongoing.
- AquaFlow Glaucoma Device: Received a Medical Device License in Canada (Jan 2001). FDA advisory committee recommended approval in Nov 2000, pending labeling modifications and a two-year post-approval study.
- Sonic WAVE Phacoemulsification System: Received CE Mark in March 2001 for European sales. A direct U.S. sales force has been established.
- Collamer IOL: FDA approved for U.S. marketing in April 2000. Manufacturing began in September 2000.
Risks and Contingencies:
- Liquidity and Covenants: The company was not in compliance with the net income covenant of its domestic line of credit as of year-end but obtained a waiver from the lender. It is seeking alternative financing to pay down the $5.7 million outstanding balance.
- Legal Proceedings: Significant disputes exist with the Canon joint venture partners (arbitration pending) and former CEO John R. Wolf (litigation regarding termination and stock options).
- Regulatory: Future growth is heavily dependent on FDA approvals for the ICL and AquaFlow device.
- Foreign Exchange: International sales expose the company to currency fluctuation risks, though most transactions are denominated in U.S. dollars.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of the waiver obtained from the domestic lender and the company's ability to secure alternative financing to pay down the $5.7 million line of credit.
- Restructuring Accruals: Confirm the remaining $2.2 million in accrued restructuring charges and the timeline for cash outflows.
- Joint Venture Litigation: Monitor the arbitration proceedings with Canon regarding the Japanese joint venture and the potential for further financial impact.
- Regulatory Milestones: Track the submission and approval status of the ICL PMA application (expected early 2002) and the final FDA decision on the AquaFlow device.
- Inventory Valuation: Assess the remaining inventory levels following the $5.2 million write-off to ensure no further obsolescence charges are imminent.